Xilio Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $43.8M | $6.3M | — | — | — |
| Operating income | -$42.0M | -$60.6M | -$79.1M | -$89.1M | -$75.0M |
| Operating expenses | $85.7M | $66.9M | $79.1M | $89.1M | $75.0M |
| Cash from operations | -$5.0M | -$18.4M | -$68.6M | -$75.7M | -$80.8M |
| Capital expenditure | $518,000 | $36,000 | $486,000 | $1.9M | $1.1M |
| Free cash flow | -$5.5M | -$18.4M | -$69.1M | -$77.6M | -$81.9M |
| Total assets | $154.7M | $71.1M | $60.9M | $139.2M | $218.1M |
| Total liabilities | $119.4M | $53.5M | $24.1M | $33.5M | $32.6M |
Shares outstanding 5.8M
Annual filing data through FY ended December 31, 2025; float as of July 2, 2026.